{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:44:09Z","timestamp":1777445049257,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Biochem"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Third-generation whole PTH (1-84) parathyroid hormone (PTH) assays do not recognize the PTH 7-84 fragment whereas second-generation (intact) assays detect both 1-84 and 7-84 PTH fragments. This study aimed to compare the second-generation Roche intact PTH method with the third-generation Roche whole PTH (1-84) method, examining differences based on estimated glomerular filtration rate (eGFR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The intact PTH method and whole PTH (1-84) method were compared using 100 serum samples selected across eGFR quintiles for chronic kidney disease (CKD) stages 1\u22125 in accordance with Kidney Disease: Improving Global Outcomes (KDIGO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Method comparison based on eGFR showed that differences between both PTH methods were not significant at eGFR &gt;60\u00a0mL\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      . There was a statistically significant difference at eGFR &lt;60\u00a0mL\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      . The whole PTH (1-84) method produced lower results as eGFR decreased: CKD Stage 3 (mean difference: \u221221%; 95% confidence interval: -16 to -26%) to CKD Stage 5 (mean difference: \u221246%; 95% confidence interval: -40 to -52%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Differences observed between the two assays may be due to second-generation PTH assays overestimating PTH concentration by measuring both 1-84 PTH and C-terminal fragments, notably PTH (7-84) in patients with significant renal impairment. The whole PTH (1-84) assay may be used to monitor metabolic bone disease risk. Initial dual reporting of PTH by both methods is recommended for eGFR &lt;60\u00a0mL\/min to educate users due to the difference in results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00045632251356826","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:55:52Z","timestamp":1750726552000},"page":"98-104","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["A method comparison of the Roche intact PTH method versus the Roche whole PTH (1-84) method: Examining the differences based on eGFR"],"prefix":"10.1177","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3353-4322","authenticated-orcid":false,"given":"Byrne","family":"E","sequence":"first","affiliation":[{"name":"St. Vincent\u2019s University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-4673","authenticated-orcid":false,"given":"Twomey","family":"PJ","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crowley","family":"RK","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"McKenna","family":"MJ","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kilbane","family":"M","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09580911"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2013.01.016"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2015.03.018"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPLGCZR7IPVHA7"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr614"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2020.12.022"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1590\/2359-3997000000183"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2013-1027"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2011.00926.x"},{"key":"e_1_3_5_11_2","first-page":"1","article-title":"KDIGO CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","unstructured":"KDIGO CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1\u2013150.","journal-title":"Kidney Int Suppl"},{"key":"e_1_3_5_12_2","volume-title":"EP15-A3 user verification of precision and estimation of bias","author":"Carey RN","year":"2014","unstructured":"Carey RN. EP15-A3 user verification of precision and estimation of bias. 3rd ed. CLSI (Clinical and Laboratories Standards Institute), 2014.","edition":"3"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01709.x"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1258\/000456306776021616"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2016.10.016"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/15-127"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2012-0485"},{"key":"e_1_3_5_18_2","unstructured":"Roche D. Cobas\u00ae Elecsys PTH (1-84) assay instructions for use on cobas e602 systems. 2018;08V5.0."},{"key":"e_1_3_5_19_2","unstructured":"Roche Diagnostics. Cobas\u00ae Elecsys Intact PTH assay instructions for use on cobas e602 systems. 2018;07V24.0."},{"key":"e_1_3_5_20_2","first-page":"28","volume-title":"Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy","author":"National Institute for Health and Clinical Excellence (Great Britain)","year":"2007","unstructured":"National Institute for Health and Clinical Excellence (Great Britain). Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. London: National Institute for Health and Clinical Excellence, 2007, p. 28."},{"key":"e_1_3_5_21_2","unstructured":"KDOQI. Clinical practice guideline for chronic kidney disease evaluation classification and stratification. https:\/\/www.kidney.org (2002 Accessed 31 Mar 2023)."},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2010.027"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.06.023"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2004.022186"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002363"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2017.37.5.381"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12690"}],"container-title":["Annals of Clinical Biochemistry: International Journal of Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00045632251356826","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00045632251356826","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00045632251356826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:25:42Z","timestamp":1777379142000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00045632251356826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/00045632251356826"],"URL":"https:\/\/doi.org\/10.1177\/00045632251356826","relation":{},"ISSN":["0004-5632","1758-1001"],"issn-type":[{"value":"0004-5632","type":"print"},{"value":"1758-1001","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]}}}